Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy, duration, and safety of the synthetic opioid pentamorphone in the treatment of acute postoperative pain were evaluated in a randomized, double-blind study of 72 patients given 0.08, 0.16, or 0.24 micrograms/kg of pentamorphone or a placebo intravenously in the recovery room after major abdominal or orthopedic surgery. Only patients given 0.24 micrograms/kg of pentamorphone experienced decreased pain intensity and increased sedation, both transient in duration. Although the two higher doses of pentamorphone delayed the patient's request for supplemental morphine, the total amount of morphine required within the first hour was not different between treatments. No acute cardiorespiratory changes were observed. Pentamorphone (0.08-0.24 micrograms/kg) was ineffective for treating acute postoperative pain after major surgery.
 ...
PMID:Pentamorphone for management of postoperative pain. 170 14

We evaluated the analgesic properties of 14-beta-n-pentylaminomorphinone (pentamorphone), a new morphinan derivative, in 23 male volunteers divided into 6 groups who were given either placebo (1 per group) or 0.015, 0.03, 0.06, 0.12, 0.24, 0.48 microgram.kg-1 pentamorphone intravenously. Analgesia was evaluated by the maximal tolerance to a spring-loaded rod on the tibia and manubrium. Analgesic assessments and arterial blood samples were taken prior to and at set time intervals following drug administration. Pentamorphone produced a linear increase in pain tolerance with increasing dose as well as a dose-dependent depression of ventilation. Pentamorphone had no effect on blood pressure or heart rate in the doses used. Plasma histamine levels at 5 minutes were not elevated with any of the dosages. Pentamorphone appears to be an analgesic with clinically tolerable side effects in the range 0.12 to 0.24 microgram.kg-1 that merits further evaluation under clinical conditions.
 ...
PMID:Evaluation of pentamorphone in humans: a new potent opiate. 246 8